Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients

Yamamoto,Nobuyuki; Kozaki,Aiko; Hartomo,Tri  Budi; Yanai,Tomoko; Hasegawa,Daiichiro; Kawasaki,Keiichiro; Kosaka,Yoshiyuki; Matsuo,Masafumi; Hirase,Satoshi; Mori,Takeshi; Hayakawa,Akira; Iijima,Kazumoto; Nishio,Hisahide; Nishimura,Noriyuki

doi:10.3892/ol.2015.3710

Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients

Authors:
- Nobuyuki Yamamoto
- Aiko Kozaki
- Tri Budi Hartomo
- Tomoko Yanai
- Daiichiro Hasegawa
- Keiichiro Kawasaki
- Yoshiyuki Kosaka
- Masafumi Matsuo
- Satoshi Hirase
- Takeshi Mori
- Akira Hayakawa
- Kazumoto Iijima
- Hisahide Nishio
- Noriyuki Nishimura
View Affiliations

Affiliations: Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan, Department of Hematology and Oncology, Kobe Children's Hospital, Kobe 654‑0081, Japan, Department of Epidemiology, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan, Department of Medical Rehabilitation, Kobe Gakuin University, Kobe 651‑2180, Japan
Published online on: September 16, 2015 https://doi.org/10.3892/ol.2015.3710
Pages: 3228-3232

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma is an aggressive solid tumor that leads to tumor relapse in more than half of high‑risk patients. Minimal residual disease (MRD) is primarily responsible for tumor relapses and may be detected in peripheral blood (PB) and bone marrow (BM) samples. To evaluate the disease status and treatment response, a number of MRD detection protocols based on either common or distinct markers for PB and BM samples have been reported. However, the correlation between the expression of MRD markers in PB and BM samples remains elusive in the clinical samples. In the present study, the expression of 11 previously validated MRD markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) was determined in 23 pairs of PB and BM samples collected from seven high‑risk neuroblastoma patients at the same time point, and the sample was scored as MRD‑positive if one of the MRD markers exceeded the normal range. Although the number of MRD‑positive samples was not significantly different between PB and BM samples, the two most sensitive markers for PB samples (CRMP1 and KIF1A) were different from those for BM samples (PHOX2B and DBH). There was no statistically significant correlation between the expression of MRD markers in the PB and BM samples. These results suggest that MRD markers were differentially expressed in PB and BM samples from high-risk neuroblastoma patients.

View Figures

View References

1	Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003. View Article : Google Scholar : PubMed/NCBI
2	Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
3	Maris JM: Recent advances in neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
4	Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G and Klein CA: Systemic spread is an early step in breast cancer. Cancer Cell. 13:58–68. 2008. View Article : Google Scholar : PubMed/NCBI
5	Rhim AD, Mirek ET, Aiello NM, et al: EMT and dissemination precede pancreatic tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
6	Kang Y and Pantel K: Tumor cell dissemination: Emerging biological insights from animal models and cancer patients. Cancer Cell. 23:573–581. 2013. View Article : Google Scholar : PubMed/NCBI
7	Müller V, Alix-Panabières C and Pantel K: Insights into minimal residual disease in cancer patients: Implications for anti-cancer therapies. Eur J Cancer. 46:1189–1197. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lin H, Balic M, Zheng S, Datar R and Cote RJ: Disseminated and circulating tumor cells: Role in effective cancer management. Crit Rev Oncol Hematol. 77:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
9	Mordant P, Loriot Y, Lahon B, Castier Y, Lesèche G, Soria JC, Massard C and Deutsch E: Minimal residual disease in solid neoplasia: New frontier or red-herring? Cancer Treat Rev. 38:101–110. 2012. View Article : Google Scholar : PubMed/NCBI
10	Viprey VF, Lastowska MA, Corrias MV, Swerts K, Jackson MS and Burchill SA: Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol. 216:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
11	Cheung IY, Feng Y, Gerald W and Cheung NK: Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res. 14:7020–7027. 2008. View Article : Google Scholar : PubMed/NCBI
12	Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE and Tytgat GA: Detecting minimal residual disease in neuroblastoma: The superiority of a panel of real-time quantitative PCR markers. Clin Chem. 55:1316–1326. 2009. View Article : Google Scholar : PubMed/NCBI
13	Hartomo TB, Kozaki A, Hasegawa D, Van Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y, Ohashi H, et al: Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells. Oncol Rep. 29:1629–1636. 2013.PubMed/NCBI
14	Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE and Tytgat GA: The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer. 47:1193–1202. 2011. View Article : Google Scholar : PubMed/NCBI
15	Yáñez Y, Grau E, Oltra S, Cañete A, Martínez F, Orellana C, Noguera R, Palanca S and Castel V: Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. J Cancer Res Clin Oncol. 137:1263–1272. 2011. View Article : Google Scholar : PubMed/NCBI
16	Corrias MV, Haupt R, Carlini B, Cappelli E, Giardino S, Tripodi G, Tonini GP, Garaventa A, Pistoia V and Pistorio A: Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatr Blood Cancer. 58:43–49. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
18	Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B, Dicks-Mireaux C, Frappaz D, et al: The international neuroblastoma risk groups (INRG): a preliminary report. Eur J Cancer. 33:2113–2116. 1997. View Article : Google Scholar : PubMed/NCBI
19	Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE and Tytgat GA: Stability of PCR targets for monitoring minimal residual disease in neuroblastoma. J Mol Diagn. 14:168–175. 2012. View Article : Google Scholar : PubMed/NCBI
20	Vermeulen L, de Sousa e Melo F, Richel DJ and Medema JP: The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 13:e83–e89. 2012. View Article : Google Scholar : PubMed/NCBI
21	Plaks V, Koopman CD and Werb Z: Cancer: Circulating tumor cells. Science. 341:1186–1188. 2013. View Article : Google Scholar : PubMed/NCBI
22	Alix-Panabières C and Pantel K: Challenges in circulating tumour cell research. Nat Rev Cancer. 14:623–631. 2014. View Article : Google Scholar : PubMed/NCBI
23	Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, et al: Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 31:539–544. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, et al: Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 20:897–903. 2014. View Article : Google Scholar : PubMed/NCBI